James Lisak, MD
Neurology · North Dartmouth, MANPI 1336182260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Argenx US, Inc. at 33.3% of the total. Reporting peaked in 2023 at $219 and has fallen 92.0% since, to $17 in 2024. That places this record below the midpoint for neurology clinicians in MA, where the typical reported total is $350.
Across 18 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$125
- Novartis$77
- UCB, Inc.$65
- AstraZeneca$49
- Bristol Myers Squibb$19
- Genentech USA, Inc.$15
- plus $26 from 2 others
What the payments were for
- Food & beverage$34190%
- Education$3610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 5 | $125 |
| Novartis | 4 | $77 |
| UCB, Inc. | 2 | $65 |
| AstraZeneca | 3 | $49 |
| Bristol Myers Squibb | 1 | $19 |
| Genentech USA, Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$377 in reported general payments places this provider in the 50th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DilantinPhenytoin Sodium Extended | 17 | $7,083 |
| Divalproex Sodium | 92 | $6,283 |
| Levetiracetam | 98 | $5,409 |
| Carbamazepine | 61 | $4,524 |
| Pimozide | 16 | $4,488 |
| Memantine Hcl ErMemantine Hcl | 25 | $4,134 |
| Phenytoin Sodium Extended | 105 | $3,694 |
| Carbamazepine ErCarbamazepine | 25 | $3,192 |
| Clorazepate Dipotassium | 21 | $2,886 |
| Oxcarbazepine | 48 | $2,789 |
| Lacosamide | 40 | $2,173 |
| Lamotrigine | 63 | $1,951 |
| Phenytoin | 60 | $1,831 |
| Phenobarbital | 68 | $1,527 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 37 | $1,425 |
Paid to pharmacies, not to this prescriber.
Other neurology in North Dartmouth
- Christopher WrightBoston$2.5M
- Shivang JoshiWestborough$1.2M
- Egilius SpieringsWellesley Hills$680K
- Thomas ScammellBoston$617K
- Salvatore NapoliFoxboro$613K
- Alfred SandrockBoston$490K
- Joshua KatzWellesley$462K
- Guy BuckleBrookline$450K
- Pushpa NarayanaswamiBoston$420K
- Kenneth GorsonWellesley$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.